Ansgar Schuffenhauer

Dr. Ansgar Schuffenhauer

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2009 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
Peter ErtlPeter Ertl
Peter Ertl
ASAnsgar Schuffenhauer
Ansgar Schuffenhauer
A method to estimate ease of synthesis (synthetic accessibility) of drug-like molecules is needed in many areas of the drug discovery process. The development and validation of such a method that is able to characterize molecule synthetic accessibility as a score between 1 (easy to make) and 10 (very difficult to make) is described in this article.

2 December 2006 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
ASAnsgar Schuffenhauer
Ansgar Schuffenhauer
Peter ErtlPeter Ertl
Peter Ertl
SRSilvio Roggo
Silvio Roggo
SWStefan Wetzel
Stefan Wetzel
MKMarcus A. Koch
Marcus A. Koch
HWHerbert Waldmann
Herbert Waldmann

29 August 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
WHWouter Heyndrickx
Wouter Heyndrickx
LMLewis Mervin
Lewis Mervin
TMTobias Morawietz
Tobias Morawietz
NSNoé Sturm
Noé Sturm
LFLukas Friedrich
Lukas Friedrich
HCHugo Ceulemans
Hugo Ceulemans
Federated multipartner machine learning has been touted as an appealing and efficient method to increase the effective training data volume and thereby the predictivity of models, particularly when the generation of training data is resource-intensive. In the landmark MELLODDY project, indeed, each of ten pharmaceutical companies realized aggregated improvements on its own classification or regression models through federated learning. To this end, they leveraged a novel implementation extending multitask learning across partners, on a platform audited for privacy and security. The experiments involved an unprecedented cross-pharma data set of 2.6+ billion confidential experimental activity data points, documenting 21+ million physical small molecules and 40+ thousand assays in on-target and secondary pharmacodynamics and pharmacokinetics. Appropriate complementary metrics were developed to evaluate the predictive performance in the federated setting. In addition to predictive performance increases in labeled space, the results point toward an extended applicability domain in federated learning. Increases in collective training data volume, including by means of auxiliary data resulting from single concentration high-throughput and imaging assays, continued to boost predictive performance, albeit with a saturating return. Markedly higher improvements were observed for the pharmacokinetics and safety panel assay-based task subsets.

1 August 2005 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
ASAnsgar Schuffenhauer
Ansgar Schuffenhauer
SRSimon Ruedisser
Simon Ruedisser
AMAndreas Marzinzik
Andreas Marzinzik
WJWolfgang Jahnke
Wolfgang Jahnke
PSPaul Selzer
Paul Selzer
EJEdgar Jacoby
Edgar Jacoby
According to Hanns model of molecular complexity an increased probability of detection binding to a target protein can be expected when small, low complex molecular fragments are screened with high sensitivity instead of fullsized ligands with lower sensitivity. Analysis of the HTS summary data of Novartis and comparison with NMR screening results obtained on generic fragment libraries indicate this expectation to be true with hitrates of 0.001% - 0.151% observed in the identification of ligands with an IC50 threshold in the micromolar range in an HTS setup and hitrates above or equal to 3% observed in NMR screening of fragments with an affinity threshold in the millimolar range. It is however necessary to keep in mind that the sets of target studied were not identical for both method and the experience in NMR screening is too limited for a final conclusion. The term hitrate as used here reflects only the success rate in the observation of ligand binding event. It must not be confused with the overall success rate of fragment and high throughput screening in the lead finding process, which can be entirely different, since the steps required to follow-up a ligand binding event to a lead are different for both methods. A survey of fragment-based lead discovery case studies given in the literature shows that in approximately half of the cases the initial hit fragment was discovered by screening a generic library, whereas in the other cases some knowledge about an initial ligands or the protein binding site has been used, whereas systematic virtual screening of fragment databases has been only rarely reported. As comparatively high hitrates were obtained, further consideration to optimize the generic fragment screening library were directed to the chemical tractability of the fragment. As several functional groups preferred by chemists for modification and linking of the fragments are also preferentially involved in interactions between the fragments and the target protein, a set of screening fragments was derived from chemical building blocks by masking its linker group by a chemical transformation which can be later on used in the chemical follow-up of the fragment hit. For example primary amines can be masked as acetamides. If the screening fragment is active the related building block can then be used for synthesis of a follow-up library.

14 December 2005 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
ASAnsgar Schuffenhauer
Ansgar Schuffenhauer
NBNathan Brown
Nathan Brown
PSPaul Selzer
Paul Selzer
Peter ErtlPeter Ertl
Peter Ertl
EJEdgar Jacoby
Edgar Jacoby

3 November 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAnsgar Schuffenhauer
Ansgar Schuffenhauer
NSNadine Schneider
Nadine Schneider
SHSamuel Hintermann
Samuel Hintermann
DADouglas Auld
Douglas Auld
JBJutta Blank
Jutta Blank
DBDaniel K. Baeschlin
Daniel K. Baeschlin